Literature DB >> 28815411

Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents.

Abeer M El-Naggar1, Mohsen M Abou-El-Regal2, Souad A El-Metwally3, Farag F Sherbiny4,5, Ibrahim H Eissa6.   

Abstract

Thymidylate synthase (TS), one of folate-dependent enzymes, is a key and well-recognized target for anticancer agents. In this study, a series of 6-aryl-5-cyano thiouracil derivatives were designed and synthesized in accordance with essential pharmacophoric features of known TS inhibitors. Nineteen compounds were screened in vitro for their anti-proliferative activities toward HePG-2, MCF-7, HCT-116, and PC-3 cell lines. Compounds [Formula: see text], [Formula: see text], and 24 exhibited high anti-proliferative activity, comparable to that of 5-fluorouracil. Additionally, ten compounds with potent anti-proliferative activities were further evaluated for their ability to inhibit TS enzyme. Six compounds ([Formula: see text], [Formula: see text], [Formula: see text], 22, 23 and 24) demonstrated potent dose-related TS inhibition with [Formula: see text] values ranging from 1.57 to [Formula: see text]. The in vitro TS activity results were consistent with those of the cytotoxicity assay where the most potent anti-proliferative compounds of the series showed good TS inhibitory activity comparable to that of 5-fluorouracil. Furthermore, molecular docking studies were carried out to investigate the binding pattern of the designed compounds with the prospective target, TS (PDB-code: 1JU6).

Entities:  

Keywords:  6-Aryl-5-cyano thiouracil; Anticancer; Docking; Thymidylate synthase

Mesh:

Substances:

Year:  2017        PMID: 28815411     DOI: 10.1007/s11030-017-9776-1

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  33 in total

1.  Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues.

Authors:  M Macchia; S Barontini; S Bertini; V Di Bussolo; S Fogli; E Giovannetti; E Grossi; F Minutolo; R Danesi
Journal:  J Med Chem       Date:  2001-11-08       Impact factor: 7.446

2.  Mechanism of influence of phosphorylation on serine 124 on a decrease of catalytic activity of human thymidylate synthase.

Authors:  Adam Jarmuła; Tomasz Fraczyk; Piotr Cieplak; Wojciech Rode
Journal:  Bioorg Med Chem       Date:  2010-04-09       Impact factor: 3.641

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

5.  Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones.

Authors:  S E Webber; T M Bleckman; J Attard; J G Deal; V Kathardekar; K M Welsh; S Webber; C A Janson; D A Matthews; W W Smith
Journal:  J Med Chem       Date:  1993-03-19       Impact factor: 7.446

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  2-Thio derivatives of dUrd and 5-fluoro-dUrd and their 5'-monophosphates: synthesis, interaction with tumor thymidylate synthase, and in vitro antitumor activity.

Authors:  M Bretner; T Kulikowski; J M Dzik; M Balińska; W Rode; D Shugar
Journal:  J Med Chem       Date:  1993-11-12       Impact factor: 7.446

9.  Parallel synthesis of 5-cyano-6-aryl-2-thiouracil derivatives as inhibitors for hepatitis C viral NS5B RNA-dependent RNA polymerase.

Authors:  Yili Ding; Jean-Luc Girardet; Kenneth L Smith; Gary Larson; Brett Prigaro; Jim Z Wu; Nanhua Yao
Journal:  Bioorg Chem       Date:  2005-12-19       Impact factor: 5.275

10.  An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes.

Authors:  Mahreen Arooj; Sugunadevi Sakkiah; Guang ping Cao; Keun Woo Lee
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more
  3 in total

1.  Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5(4H)-ones as potential tubulin polymerization inhibitors targeting the colchicine binding site.

Authors:  Abeer M El-Naggar; Ibrahim H Eissa; Amany Belal; Amira A El-Sayed
Journal:  RSC Adv       Date:  2020-01-15       Impact factor: 4.036

2.  Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers.

Authors:  Heba S A Elzahabi; Eman S Nossier; Rania A Alasfoury; May El-Manawaty; Sara M Sayed; Eslam B Elkaeed; Ahmed M Metwaly; Mohamed Hagras; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

3.  Novel Anthraquinone Compounds Inhibit Colon Cancer Cell Proliferation via the Reactive Oxygen Species/JNK Pathway.

Authors:  Yuying Li; Fang Guo; Yingying Guan; Tinggui Chen; Kaiqing Ma; Liwei Zhang; Zhuanhua Wang; Qiang Su; Liheng Feng; Yaoming Liu; Yuzhi Zhou
Journal:  Molecules       Date:  2020-04-04       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.